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Abstract
Objectives—Absent outcome data from randomized clinical trials, management of hypertension
in acute ischaemic stroke remains controversial. Data from human participants have failed to
resolve the question whether cerebral blood flow (CBF) in the peri-infarct region will decrease due
to impaired autoregulation when systemic mean arterial pressure (MAP) is rapidly reduced.
Methods—Nine participants, 1–11 days after hemispheric ischaemic stroke, with systolic blood
pressure more than 145 mmHg, underwent baseline PET measurements of regional CBF.
Intravenous nicardipine infusion was then used to rapidly reduce mean arterial pressure 16 ± 7
mmHg and CBF measurement was repeated.
Results—Compared with the contralateral hemisphere, there were no significant differences in
the percent change in CBF in the infarct (P = 0.43), peri-infarct region (P = 1.00) or remainder of
the ipsilateral hemisphere (P = 0.50). Two participants showed CBF reductions of greater than
19% in both hemispheres.
Conclusion—In this study, selective regional impairment of CBF autoregulation in the infarcted
hemisohere to reduced systemic blood pressure was not a characteristic of acute cerebral
infarction. Reductions in CBF did occur in some individuals, but it was bihemispheric
phenomenon that likely was due to an upward shift of the autoregulatory curve as a consequence
of chronic hypertension. These results indicate individual monitoring of changes in global CBF,
such as with bedside transcranial Doppler, may be useful to determine individual safe limits when
MAP is lowered in the setting of acute ischaemic stroke. The benefit of such an approach can only
be demonstrated by clinical trials demonstrating improved patient outcome.
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In the absence of outcome data from randomized clinical trials, the management of
hypertension in acute ischaemic stroke remains controversial [1–3]. Under normal
conditions, changes in mean arterial pressure (MAP) over a wide range have little effect on
cerebral blood flow (CBF) [4]. In most studies, the limits of autoregulation in normal
participants are from approximately 70–150 mmHg [4,5]. [A contrasting viewpoint has been
offered by Schmidt et al. [6] who used a new computer method to determine the lower limit
of autoregulation at 85 mmHg.] Below the lower limit of autoregulation, further decreases in
MAP lead to a decrease in CBF. Chronic arterial hypertension shifts the lower limit of
autoregulation upwards, such that reductions in whole brain (global) CBF occur at higher
MAP [7].
A series of pioneering human CBF studies using intra-carotid radiotracer injection following
acute ischaemic stroke showed focal impairment of autoregulation to changes in systemic
arterial blood pressure. Most of these studies employed increases in blood pressure only and
none could distinguish the infarct from the peri-infarct region [8–11]. Recently, several
studies of blood pressure reduction in hours or days following acute ischaemic stroke using
different methods for CBF measurement have found no evidence of autoregulatory
impairment in patients with recent ischaemic stroke [12]. However, due to a variety of
methodological shortcomings, these studies have failed to resolve the question whether CBF
in the peri-infarct (penumbra) region will decrease when systemic arterial pressure is
quickly reduced due to regional impairment of autoregulation [12]. These studies were either
performed with SPECT or xenon-CT (which have limited spatial resolution and thus may
have failed to detect localized peri-infarct changes), used longer acting oral agents to reduce
MAP, did not measure the effects of MAP reduction on CBF acutely or failed to report both
hemispheric and peri-infarct values [12]. To provide more data relevant to the clinical
situation in acute ischaemic stroke when rapid blood pressure reduction is contemplated, we
performed a high resolution, quantitative PET study in nine patients with hemispheric stroke




Patients hospitalized at Barnes–Jewish Hospital with acute ischaemic stroke were eligible
for inclusion if they met the following criteria: age 18 years or older, diagnosis of
hemispheric cerebral infarction by history, clinical examination, systolic blood pressure
more than 145 mmHg by intra-arterial blood pressure recording at the completion of the
baseline CBF measurements, and computed tomography (CT) scan within the previous 14
days. CT of the head did not need to show an appropriate focal area of decreased
attenuation, but was required to rule out other conditions such as intracranial haemorrhage,
tumour, etc. The following were reasons for exclusion: inability to cooperate with the
performance of a detailed neurological examination and PET, decreased level of
consciousness (NIHSS 1a > 2) and high baseline NIHSS (left hemisphere > 20 or right
hemisphere > 15), pregnancy, compelling clinical reason to lower blood pressure (such as
ongoing cardiac ischaemia, congestive heart failure, aortic dissection, hypertensive
encephalopathy, malignant hypertension or acute renal failure), bilateral carotid artery
stenosis at least 70%, concurrent treatment with alpha-1 receptor blockers (doxazosin,
terazosin, prazosin) or hydralazine, known allergy to calcium channel blockers, or
haemodynamically significant aortic valve stenosis.
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Stroke onset was defined by the onset of symptoms. If the participant awoke with symptoms
or if the exact onset of symptoms could not be determined, the time of onset was considered
to be the time at which the patient was last known to be at his usual state of health. The type
of ischaemic stroke was classified according to the Oxfordshire Community Stroke Project.
This is a classification of subtypes of cerebral infarction (total or partial anterior circulation
infarction, lacunar infarction, or posterior circulation infarction) based on clinical data only
[13].
PET studies
All participants were studied on the Siemens model 961 ECAT EXACT HR 47 PET scanner
(Siemens/CTI, Knoxville, Tennessee, USA) located in the Neurology-Neurosurgery
Intensive Care Unit at Barnes-Jewish Hospital. This scanner collects 47 contiguous
transverse slices encompassing an axial field of view of 15 cm. Spatial resolution is
approximately 4.3 mm full width at half maximum (FWHM) at the centre of the field of
view. All patients had one radial arterial catheter placed for blood sampling and two venous
catheters placed in a peripheral arm vein for administration of radiotracers and for
nicardipine infusion. Attenuation data were obtained using 68Ge-68Ga rotating rod sources
to enable quantitative reconstruction of subsequent emission scans. The PET scanner was
calibrated for conversion of PET counts to quantitative radiotracer concentrations using
standards counted in a well counter. Emission data were obtained in the 2D mode (interslice
septa extended).
CBF was measured with an adaptation of the Kety autoradiographic method using
intravenous bolus injection of 50 mCi of 15O labelled water [14,15]. Simultaneously with
acquisition of the PET emission data, arterial blood was sampled and the arterial activity
curve was determined using a scintillation counter calibrated to the same well counter as the
PET scanner. The arterial time-radioactivity curve recorded by the sampler was corrected for
delay and dispersion using previously determined parameters. Baseline measurements of
CBF were performed in triplicate. Participants whose systolic blood pressure was more than
145 mmHg at the end of the third baseline CBF scan received an intravenous infusion of
nicardipine starting at 2.5 mg/h upto a maximum of 15 mg/h to achieve a reduction in MAP
by 15 ± 5 mmHg from baseline in two steps of 7.5 mmHg. A clinical assessment was
performed at each blood pressure step. Mild sedation with fentanyl 25–100 μg IV upto a
total dose of 300 μg was used as needed.
Immediately after the PET scan patients who had not had MRI performed for clinical
purposes underwent MRI including T2 and diffusion weighted studies to delineate the
infarct. Participants with contraindications for MRI such as history or documentation of
implanted ferromagnetic material or other devices (e.g. cardiac pacemaker) or
claustrophobia underwent CT.
Written informed consent was obtained from all participants or, if the participant was
incapable of giving informed consent, from the participant’s legally authorized
representative in accordance with Missouri state law. This protocol was approved by the
Washington University Human Studies Committee (IRB).
Data analysis
PET 2D-acquisitions following bolus water injection were reconstructed with measured
attenuation and scatter corrections using filtered backprojection to a 3D resolution of 4.3
mm FWHM. Seven participants had magnetic resonance (MR) imaging and two had CT
imaging. These were standard clinical scans from a variety of scanners (Siemens Magnetom
Vision, Expert, Symphony, or Trio for MRI and Siemens Sensation 16 or Somatom Plus 4
Powers et al. Page 3













for CT). Anatomical images had less than 1 mm in-plane resolution but had slice sampling
ranging from 3.0–7.8 mm. All PET images were coregistered to each other using Automated
Image Registration software (AIR, Roger Woods, University of California, Los Angeles,
California, USA) [16]. Anatomical images were also coregistered and resliced to the PET
images using AIR [17].
The ipsilateral hemisphere was divided into areas of infarction, the peri-infarct area and the
remainder. Brain tissue was segmented from either MR FLAIR or CT. Infarcted areas
(ranging from 0.5–340 ml) were identified either from MR diffusion weighted images or
CT. One cm annular peri-infarct regions were created by 2D dilation around each infarct,
conditionally restricted to noninfarcted ipsilateral brain tissue. The remaining ipsilateral
hemispheric CBF measurements excluded the infarct and peri-infarct regions. All CBF
values were computed using mean PET counts within the volume of interest on the original
PET images (4.3 mm resolution). Mean counts were then converted to CBF (ml/100 g per
min) [15].
In a previous study of nine normal individuals in which 18 sets of four sequential CBF
measurements at stable clamped plasma glucose were performed, the maximum decrease in
hemispheric CBF between the mean of the first three studies and the fourth study was 18.9%
[18]. Therefore, we considered a reduction in contralateral hemispheric CBF in an individual
subject more than 19% between the mean of the three baseline studies and the study during
blood pressure reduction to be abnormal.
With selective regional impairment of autoregulation, there will be a consistently greater
decrease in CBF during blood pressure reduction in the region with selective impairment
than in the contralateral control hemisphere. To determine if this was the case, we compared
the percentage change in CBF in the contralateral control hemisphere to the infarct, the peri-
infarct region and the remainder of the ipsilateral hemisphere by paired t-test. All statistical
analyses were performed with SPSS 16.0 for Windows (SPSS, Inc, Chicago, Illinois, USA).
Results
Twelve participants were enrolled in this study. One participant was unable to undergo PET
because he could not lie still. PET studies could not be performed in another because of
inability to insert a radial artery catheter. One was found susequently to have a pontine
infarct. Clinical characteristics and physiological data during PET for the remaining nine
participants are shown in the Tables 1 and 2. Two received fentanyl during the the baseline
series of scans: Case 8 62.5 μg and Case 9 25 μg. Carotid ultrasound in seven participants
and arteriography in one showed less than 50% cervical stenosis bilaterally in all. Case 7 did
not undergo carotid imaging because her thalamic infarct was not in the carotid arterial
territory.
IV nicardipine was administered starting at 2.5 mg/h and then adjusted every 10 min. MAP
was reduced by 8–30, mean 16 ± 7 (SD) mmHg over 33–83 (mean 63) min. MAP was held
constant at this level for at least several minutes prior to the CBF measurement, sufficiently
long to permit the cerebrovascular responses to MAP reduction to reach a new steady state
[19]. Six of the nine participants reached the target of 10–20 mmHg reduction (Table 3) The
percent change in CBF in the peri-infarct region (−10.9 ± 16.0%) was the the same as the
contralateral hemisphere (−10.9 ± 12.3%, P = 1.00, paired t-test). Similar data were
obtained for the remainder of the ipsilateral hemisphere. In the infarct itself, CBF changes
were more variable but still did not show a significant difference from the control
contralateral hemisphere (Table 3). Thus, there was no evidence of selective focal
impairment of autoregulation in any of the regions in the ipslateral hemisphere. In two
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participants, both contralateral and ipsilateral hemispheric CBF decreased during
pharmacological blood pressure reduction more than the maximum test–retest normal range
of 19%. One (Case 3) clinically worsened; the other (Case 6) showed no clinical change.
The PET study on Case 3 was stopped when he became neurologically worse. Details of this
case have previously been reported [20]. No other participant had a change in signs or
symptoms.
There was no correlation between any of the percentage CBF changes in any of the four
regions (infarct, peri-infarct, remaining ipsilateral hemisphere or contralateral hemipshere)
and infarct size, MAP percentage change, baseline CBF or time after onset (all r <0.18, all P
>0.66).
Discussion
In this study of nine human participants who had suffered acute ischaemic stroke within the
previous 11 days, we did not find autoregulatory impairment in the infarct, peri-infarct
region or remaining ipsilateral hemisphere during rapid reductions in systemic arterial blood
pressure. Unlike previous studies, we rapidly reduced MAP with an intravenous infusion,
used a high resolution quantitative method to measure regional CBF and report regional
CBF data from both hemispheric, the peri-infarct region and the infarct [12].
In two of our indivduals we found global reductions of hemispheric CBF with MAP
reductions. The lower levels of MAP achieved in these two indivduals were 123 and 127
mmHg, well above the normal lower limit for autoregulation. Both had longstanding
hypertension manifested by left ventricular hypertrophy on echocardiography. The findings
in these two participants are consistent with a shift upwards in the whole brain
autoregulatory curve due to chronic hypertension [5,7]. One of these two patients developed
transient worsening of his focal neurological deficit during blood pressure reduction. Such
focal worsening with blood pressure reduction has been ascribed to further reducing CBF in
presumed areas of focally impaired autoregulation in the peri-infarct region [1,21]. The
findings in this case that focal worsening occurred with global reduction in CBF suggest
another explanation: When MAP is reduced below the lower limit of autoregulation (which
may be shifted upward due to chronic hypertension), CBF will decrease uniformly in the
whole brain. In the setting of acute ischaemic stroke, neurons in the peri-infarct area with
CBF values just above the threshold for normal neuronal function will be the first to become
dysfunctional as CBF decreases globally. Thus, although the CBF reduction is uniformly
global, the symptoms may be a focal worsening of the existing neurological deficit.
The CBF responses to changes in MAP that we have measured have recently been termed
static cerebral autoregulation to differentiate them from measurements of cerebral blood
flow velocity with Doppler in response to more rapid fluctuations in MAP or ICP, termed
dynamic cerebral autoregulation [22]. Studies of dynamic autoregulation following acute
ischaemic stroke have described both unilateral and bilateral abnormalities [23]. This
methodology is not spatially sensitive enough to detect selective regional impairment in the
peri-infarct area. The physiological relation between static and dynamic autoregulation is
not clear. Abnormalities of dynamic cerebral autoregulation may be associated with normal
or abnormal static autoregulation [24,25].
Our study is based on a small number of participants, mostly with small to moderate sized
infarcts. The earliest study was performed the day after onset. All had evidence of
preexisting arterial hypertension. Therefore, these findings cannot be assumed to apply to
patients with larger infarcts, those in the very acute period or those without preexisting
hypertension.
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In conclusion, focally impaired autoregulation to reduced blood pressure in the infarct, peri-
infarct area and remaining ipsilateral hemisphere was not a characteristic of acute cerebral
infarction in this study. When blood pressure was lowered, reductions in global cerebral
blood flow did occur in some individuals. Thus, the CBF response to MAP reduction in
hypertensive patients with acute ischaemic stroke was primarily a global phenomenon and
varied from individual to individual. This is similar to patients with chronic arterial
hypertension without stroke and is likely related to a variable upward shift of the
autoregulatory curve as a consequence of chronic hypertension [4,5,7]. Therefore, individual
monitoring of changes in global CBF, such as with bedside transcranial Doppler, may be
useful to determine individual safe lower limits when MAP is lowered in the setting of acute
ischaemic stroke. However, the benefit of such an approach can only be demonstrated by
clinical trials demonstrating improved patient outcome.
Acknowledgments
Sources of Support: This research was supported by the following grants from the National Institutes of Health:
NS35966 and NS44885.
Abbreviations
CBF cerebral blood flow
CT computed tomography
FWHM full width at half maximum
MAP mean arterial pressure
References
1. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early
management of adults with ischemic stroke: a guideline from the American Heart Association/
American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular
Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and
Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy
of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke
2007;38:1655–1711. [PubMed: 17431204]
2. Spengos K, Tsivgoulis G, Zakopoulos N. Blood pressure management in acute stroke: a long-
standing debate. Eur Neurol 2006;55:123–135. [PubMed: 16682796]
3. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc
Dis 2008;25:457–507. [PubMed: 18477843]
4. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev
1990;2:161–192. [PubMed: 2201348]
5. Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of brain circulation in severe
arterial hypertension. Br Med J 1973;1:507–510. [PubMed: 4692673]
6. Schmidt JF, Waldemar G, Vorstrup S, Andersen AR, Gjerris F, Paulson OB. Computerized analysis
of cerebral blood flow autoregulation in humans: validation of a method for pharmacologic studies.
J Cardiovasc Pharmacol 1990;15:983–988. [PubMed: 1694922]
7. Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients. The modifying
influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced
hypotension. Circulation 1976;53:720–727. [PubMed: 815061]
8. Hoedt-Rasmussen K, Skinhoj E, Paulson O, Ewald J, Bjerrum JK, Fahrenkrug A, et al. Regional
cerebral blood flow in acute apoplexy. The ‘luxury perfusion syndrome’ of brain tissue. Arch
Neurol 1967;17:271–281. [PubMed: 6053570]
Powers et al. Page 6













9. Paulson OB. Regional cerebral blood flow in apoplexy due to occlusion of the middle cerebral
artery. Neurology 1970;20:63–77. [PubMed: 5460771]
10. Agnoli A, Fieschi C, Bozzao L, Battistini N, Prencipe M. Autoregulation of cerebral blood flow.
Studies during drug-induced hypertension in normal subjects and in patients with cerebral vascular
diseases. Circulation 1968;38:800–812. [PubMed: 5677964]
11. Paulson OB, Lassen NA, Skinhoj E. Regional cerebral blood flow in apoplexy without arterial
occlusion. Neurology 1970;20:125–138. [PubMed: 5460701]
12. Sare GM, Gray LJ, Bath PM. Effect of antihypertensive agents on cerebral blood flow and flow
velocity in acute ischaemic stroke: systematic review of controlled studies. J Hypertens
2008;26:1058–1064. [PubMed: 18475140]
13. Anderson CS, Taylor BV, Hankey GJ, Stewart-Wynne EG, Jamrozik KD. Validation of a clinical
classification for subtypes of acute cerebral infarction. J Neurol Neurosurg Psychiatry
1994;57:1173–1179. [PubMed: 7931376]
14. Raichle ME, Martin WRW, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured
with intravenous H215O. II. Implementation and validation. J Nucl Med 1983;24:790–798.
[PubMed: 6604140]
15. Videen TO, Perlmutter JS, Herscovitch P, Raichle ME. Brain blood volume, blood flow, and
oxygen utilization measured with O-15 radiotracers and positron emission tomography: revised
metabolic computations. J Cereb Blood Flow Metab 1987;7:513–516. [PubMed: 3497165]
16. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET
images. J Comput Assist Tomogr 1992;16:620–633. [PubMed: 1629424]
17. Woods RP, Mazziota JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput
Assist Tomogr 1993;17:536–546. [PubMed: 8331222]
18. Teves D, Videen TO, Cryer PE, Powers WJ. Activation of human medial prefrontal cortex during
autonomic responses to hypoglycemia. Proc Natl Acad Sci U S A 2004;101:6217–6221. [PubMed:
15026569]
19. Kontos HA, Wei EP, Navari RM, Levasseur JE, Rosenblum WI, Patterson JL. Responses of
cerebral arteries and arterioles to acute hypotension and hypertension. Am J Physiol
1978;234:H371–H383. [PubMed: 645875]
20. Zazulia AR, Videen TO, Powers WJ. Symptomatic autoregulatory failure in acute ischemic stroke.
Neurology 2007;68:389–390. [PubMed: 17261690]
21. Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology
1993;43:461–467. [PubMed: 8450984]
22. van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: an overview of
current concepts and methodology with special focus on the elderly. J Cereb Blood Flow Metab
2008;28:1071–1085. [PubMed: 18349877]
23. Immink RV, van Montfrans GA, Stam J, Karemaker JM, Diamant M, van Lieshout JJ. Dynamic
cerebral autoregulation in acute lacunar and middle cerebral artery territory ischemic stroke.
Stroke 2005;36:2595–2600. [PubMed: 16254228]
24. Dawson SL, Panerai RB, Potter JF. Serial changes in static and dynamic cerebral autoregulation
after acute ischaemic stroke. Cerebrovasc Dis 2003;16:69–75. [PubMed: 12766365]
25. Steiner LA, Coles JP, Johnston AJ, Chatfield DA, Smielewski P, Fryer TD, et al. Assessment of
cerebrovascular autoregulation in head-injured patients: a validation study. Stroke 2003;34:2404–
2409. [PubMed: 12947157]
Powers et al. Page 7


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Hypertens. Author manuscript; available in PMC 2010 August 21.
